title: Is there a role for HbA1c in predicting mortality and morbidity outcomes after coronary artery bypass graft surgery?
abstract: A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was is there a role for HbA1c in predicting morbidity and mortality outcomes after coronary artery bypass surgery? Eleven studies presented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The studies presented analyse the relationship between preoperative HbA1c levels and postoperative outcomes following coronary artery bypass graft (CABG) in diabetic, non-diabetic or mixed patient groups. Four studies found significant increases in early and late mortality at higher HbA1c levels, regardless of a preoperative diagnosis of diabetes. One study demonstrated that 30-day survival outcomes were significantly worse in patients with previously undiagnosed diabetes and elevated HbA1c compared with those with good control [HbA1c >6%; odds ratio 1.53, confidence interval (CI) (1.24-1.91); P = 0.0005]. However, four studies of early mortality outcomes in diabetic patients only showed no significant differences between patients with normal and those with deranged HbA1c levels (P = 0.99). There were mixed reports on morbidity outcomes. Three studies identified a significant increase in infectious complications in patients with poorly controlled HbA1c, two of which were irrespective of previous diabetic status [deep sternal wound infection (P = 0.014); superficial sternal wound infection (P = 0.007) and minor infections (P = 0.006) in poorly controlled diabetics only]. Four studies presented outcomes for total length of stay (LOS). Three of these papers looked specifically at diabetic patients, of which two found no significant differences in length of stay between good and poor preoperative glycaemic control [LOS: P = 0.59 and 0.86 vs P < 0.001]. However, elevated HbA1c vs normal HbA1c was associated with prolonged stay in hospital and in intensive care unit (ICU) in patients irrespective of previous diabetic status [total LOS (P < 0.001)]. Elevated HbA1c levels were also a significant predictor of reduced intraoperative insulin sensitivity in diabetic patients (R = -0.527; P < 0.001). Furthermore, higher HbA1c levels were associated with a reduced incidence of postoperative atrial fibrillation (P = 0.001). We conclude that elevated HbA1c is a strong predictor of mortality and morbidity irrespective of previous diabetic status. In particular, the mortality risk for CABG is quadrupled at HbA1c levels >8.6%. Some studies have called into question the predictive value of HbA1c on short-term outcomes in well-controlled diabetics; however, long-term outcomes in this population have not been reported.
authors.affiliation: Ulster Hospital, South Eastern Trust, Belfast, UK.
authors.forename: Charlene
authors.initials: C
authors.lastname: Tennyson
authors.forename: Rebecca
authors.initials: R
authors.lastname: Lee
authors.forename: Rizwan
authors.initials: R
authors.lastname: Attia
mesh_terms: D019985:Benchmarking; D015415:Biomarkers / Q000097:blood; D001026:Coronary Artery Bypass / Q000009:adverse effects* / Q000401:mortality*; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D003920:Diabetes Mellitus / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D019317:Evidence-Based Medicine; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007902:Length of Stay; D011183:Postoperative Complications / Q000401:mortality; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human
keywords: Cerebrovascular accident; Coronary artery bypass graft; Deep sternal wound infection; Glycosylated haemoglobin; Myocardial infarct; Superficial sternal wound infection; World Health Organization
references.citation: J Cardiol. 2011 Mar;57(2):181-6
references.pmid: 21185154
references.citation: Scand Cardiovasc J. 2008 Dec;42(6):392-8
references.pmid: 18609043
references.citation: Can J Anaesth. 2010 Jun;57(6):565-72
references.pmid: 20221858
references.citation: Ann Thorac Surg. 2008 Nov;86(5):1431-7
references.pmid: 19049726
references.citation: J Cardiothorac Surg. 2011 Sep 02;6:104
references.pmid: 21888652
references.citation: Eur J Cardiothorac Surg. 2012 Jan;41(1):102-7
references.pmid: 21612941
references.citation: Interact Cardiovasc Thorac Surg. 2003 Dec;2(4):405-9
references.pmid: 17670084
references.citation: J Thorac Cardiovasc Surg. 2008 Sep;136(3):631-40
references.pmid: 18805264
references.citation: J Clin Endocrinol Metab. 2010 Sep;95(9):4338-44
references.pmid: 20631016
references.citation: Ann Thorac Cardiovasc Surg. 2009 Feb;15(1):18-22
references.pmid: 19262445
references.citation: Eur J Cardiothorac Surg. 2011 Apr;39(4):484-9
references.pmid: 21087870